[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fEA46v24AHPI19zxiG8vKD5KDIie75wq5VardhDbcBxA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":68,"rows":75},"Boston Scientific Corporation",[4],531,false,72,57,246609,7,486,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Coronary Artery Disease",44,{"name":18,"count":19},"Heart Failure",40,{"name":21,"count":22},"Atrial Fibrillation",27,{"name":24,"count":22},"Chronic Pain",{"name":26,"count":27},"Paroxysmal Atrial Fibrillation",20,{"name":29,"count":30},"Atherosclerosis",15,{"name":32,"count":33},"Pain",14,{"name":35,"count":36},"Bradycardia",13,[38,43,48,53,58,63],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04790370","Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism","2025-07-31","Anticoagulation with heparin",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04838769","REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men","2025-12-11","alpha blocker and 5-alpha reductase inhibitor",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06096337","Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation","2026-02-04","Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05016245","MANDARIN (S6371)","2026-02-13","TheraSphere™ Yttrium-90 Glass Microspheres",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05063565","TheraSphere With Durvalumab and Tremelimumab for HCC","2027-06","Durvalumab (Imfinzi) immunotherapy",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04394546","CHAMPION-AF Clinical Trial","2027-12","Non-Vitamin K Oral Anticoagulant",[69,70,71,72,73,74],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[76,101,123,145,163,185,207,229,267,307,333,360,386,410,454,489,523,549,576,594,620,648,666,684,710,728,757,782,800,818,836,860,898,916,934,960,982,1005,1023,1047,1072,1096,1122,1164,1190,1208,1232,1258,1284,1308,1326],{"intervention":42,"totalTrials":77,"cells":78},1,{"EARLY_PHASE1":79,"PHASE1":82,"PHASE2":84,"PHASE3":86,"PHASE4":88,"NA":99},{"trials":80,"activeCount":81},[],0,{"trials":83,"activeCount":81},[],{"trials":85,"activeCount":81},[],{"trials":87,"activeCount":81},[],{"trials":89,"activeCount":77,"soonestReadout":41},[90],{"nctId":39,"briefTitle":40,"status":91,"phases":92,"primaryCompletion":41,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":98},"ACTIVE_NOT_RECRUITING",[73],"2026-08","2021-08-02",544,[97],"Pulmonary Embolism",[42],{"trials":100,"activeCount":81},[],{"intervention":57,"totalTrials":77,"cells":102},{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":109,"PHASE4":119,"NA":121},{"trials":104,"activeCount":81},[],{"trials":106,"activeCount":81},[],{"trials":108,"activeCount":81},[],{"trials":110,"activeCount":77,"soonestReadout":56},[111],{"nctId":54,"briefTitle":55,"status":91,"phases":112,"primaryCompletion":56,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},[72],"2026-10-30","2021-09-13",92,[117],"Inoperable Hepatocellular Carcinoma",[57],{"trials":120,"activeCount":81},[],{"trials":122,"activeCount":81},[],{"intervention":62,"totalTrials":77,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":139,"PHASE4":141,"NA":143},{"trials":126,"activeCount":81},[],{"trials":128,"activeCount":81},[],{"trials":130,"activeCount":77,"soonestReadout":61},[131],{"nctId":59,"briefTitle":60,"status":91,"phases":132,"primaryCompletion":61,"completion":61,"start":133,"enrollment":134,"conditions":135,"interventions":137},[71],"2023-11-03",100,[136],"Hepatocellular Carcinoma",[62,138],"Tremelimumab immunotherapy",{"trials":140,"activeCount":81},[],{"trials":142,"activeCount":81},[],{"trials":144,"activeCount":81},[],{"intervention":138,"totalTrials":77,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":157,"PHASE4":159,"NA":161},{"trials":148,"activeCount":81},[],{"trials":150,"activeCount":81},[],{"trials":152,"activeCount":77,"soonestReadout":61},[153],{"nctId":59,"briefTitle":60,"status":91,"phases":154,"primaryCompletion":61,"completion":61,"start":133,"enrollment":134,"conditions":155,"interventions":156},[71],[136],[62,138],{"trials":158,"activeCount":81},[],{"trials":160,"activeCount":81},[],{"trials":162,"activeCount":81},[],{"intervention":67,"totalTrials":77,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":166,"activeCount":81},[],{"trials":168,"activeCount":81},[],{"trials":170,"activeCount":81},[],{"trials":172,"activeCount":81},[],{"trials":174,"activeCount":81},[],{"trials":176,"activeCount":77,"soonestReadout":66},[177],{"nctId":64,"briefTitle":65,"status":91,"phases":178,"primaryCompletion":66,"completion":66,"start":179,"enrollment":180,"conditions":181,"interventions":184},[74],"2020-10-15",3000,[21,182,183],"Stroke","Bleeding",[67],{"intervention":52,"totalTrials":77,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":197},{"trials":188,"activeCount":81},[],{"trials":190,"activeCount":81},[],{"trials":192,"activeCount":81},[],{"trials":194,"activeCount":81},[],{"trials":196,"activeCount":81},[],{"trials":198,"activeCount":77,"soonestReadout":51},[199],{"nctId":49,"briefTitle":50,"status":91,"phases":200,"primaryCompletion":51,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},[74],"2028-02-04","2023-12-28",484,[205],"Persistent Atrial Fibrillation",[52],{"intervention":47,"totalTrials":77,"cells":208},{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":217,"NA":219},{"trials":210,"activeCount":81},[],{"trials":212,"activeCount":81},[],{"trials":214,"activeCount":81},[],{"trials":216,"activeCount":81},[],{"trials":218,"activeCount":81},[],{"trials":220,"activeCount":77,"soonestReadout":46},[221],{"nctId":44,"briefTitle":45,"status":91,"phases":222,"primaryCompletion":46,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},[74],"2027-03","2021-09-15",155,[227],"Benign Prostatic Hyperplasia (BPH)",[47],{"intervention":230,"totalTrials":231,"cells":232},"Varithena®",2,{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":265},{"trials":234,"activeCount":81},[],{"trials":236,"activeCount":81},[],{"trials":238,"activeCount":81},[],{"trials":240,"activeCount":81},[],{"trials":242,"activeCount":81},[243,255],{"nctId":244,"briefTitle":245,"status":246,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT02462720","COMFORT: A Multicenter, Open-label, Randomized, Crossover Study","COMPLETED",[73],"2015-12","2016-03","2015-05",35,[253],"Varicose Veins",[230],{"nctId":256,"briefTitle":257,"status":258,"phases":259,"primaryCompletion":260,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":264},"NCT05312970","Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)","TERMINATED",[73],"2024-04-04","2023-02-10",43,[253],[230],{"trials":266,"activeCount":81},[],{"intervention":268,"totalTrials":231,"cells":269},"recombinant tissue plasminogen activator",{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":291,"NA":305},{"trials":271,"activeCount":81},[],{"trials":273,"activeCount":81},[],{"trials":275,"activeCount":81},[],{"trials":277,"activeCount":81},[278],{"nctId":279,"briefTitle":280,"status":246,"phases":281,"primaryCompletion":282,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":290},"NCT01513759","Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy",[72],"2013-02-17","2012-06-07",150,[97,286,287,288,289],"Acute Pulmonary Embolism","Sub-massive Pulmonary Embolism","Massive Pulmonary Embolism","Pulmonary Thromboembolism",[268],{"trials":292,"activeCount":81},[293],{"nctId":294,"briefTitle":295,"status":246,"phases":296,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},"NCT02396758","Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism",[73],"2019-04-30","2020-01-30","2015-06-12",131,[302],"Pulmonary Embolism and Thrombosis",[304],"Recombinant tissue plasminogen activator",{"trials":306,"activeCount":81},[],{"intervention":308,"totalTrials":77,"cells":309},"Alteplase",{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":318,"NA":331},{"trials":311,"activeCount":81},[],{"trials":313,"activeCount":81},[],{"trials":315,"activeCount":81},[],{"trials":317,"activeCount":81},[],{"trials":319,"activeCount":81},[320],{"nctId":321,"briefTitle":322,"status":246,"phases":323,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":330},"NCT02159521","Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System",[73],"2017-11-30","2014-07-10",81,[328,329],"Deep Vein Thrombosis","Post-thrombotic Syndrome",[308],{"trials":332,"activeCount":81},[],{"intervention":334,"totalTrials":77,"cells":335},"Chemotherapy",{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":358},{"trials":337,"activeCount":81},[],{"trials":339,"activeCount":81},[],{"trials":341,"activeCount":81},[],{"trials":343,"activeCount":81},[],{"trials":345,"activeCount":81},[346],{"nctId":347,"briefTitle":348,"status":349,"phases":350,"completion":351,"start":352,"enrollment":81,"conditions":353,"interventions":357},"NCT00510627","Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases","WITHDRAWN",[73],"2010-12","2007-08",[354,355,356],"Metastatic Liver Cancer","Secondary Liver Cancer","Liver Neoplasm",[334],{"trials":359,"activeCount":81},[],{"intervention":361,"totalTrials":77,"cells":362},"P2Y12 antagonist",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":384},{"trials":364,"activeCount":81},[],{"trials":366,"activeCount":81},[],{"trials":368,"activeCount":81},[],{"trials":370,"activeCount":81},[],{"trials":372,"activeCount":81},[373],{"nctId":374,"briefTitle":375,"status":246,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":382},"NCT01589978","PROMUS Element Plus US Post-Approval Study",[73],"2014-08","2018-06","2012-05",2681,[15],[383,361],"Aspirin",{"trials":385,"activeCount":81},[],{"intervention":387,"totalTrials":77,"cells":388},"3 months of dual antiplatelet therapy",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":397,"NA":408},{"trials":390,"activeCount":81},[],{"trials":392,"activeCount":81},[],{"trials":394,"activeCount":81},[],{"trials":396,"activeCount":81},[],{"trials":398,"activeCount":81},[399],{"nctId":400,"briefTitle":401,"status":246,"phases":402,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":407},"NCT02605447","EVOLVE Short DAPT Study",[73],"2019-07-17","2016-02-16",2009,[15],[387],{"trials":409,"activeCount":81},[],{"intervention":411,"totalTrials":412,"cells":413},"Thienopyridine",3,{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":450,"NA":452},{"trials":415,"activeCount":81},[],{"trials":417,"activeCount":81},[],{"trials":419,"activeCount":81},[],{"trials":421,"activeCount":81},[422,432,441],{"nctId":423,"briefTitle":424,"status":246,"phases":425,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":431},"NCT00823212","The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions",[72],"2010-09","2014-12","2009-01",1530,[15],[383,411],{"nctId":433,"briefTitle":434,"status":246,"phases":435,"primaryCompletion":436,"completion":250,"start":437,"enrollment":438,"conditions":439,"interventions":440},"NCT01500434","The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)",[72],"2011-03","2009-02",102,[15],[383,411],{"nctId":442,"briefTitle":443,"status":246,"phases":444,"primaryCompletion":445,"completion":250,"start":446,"enrollment":447,"conditions":448,"interventions":449},"NCT01510327","PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)",[72],"2010-02","2009-10",22,[15],[383,411],{"trials":451,"activeCount":81},[],{"trials":453,"activeCount":81},[],{"intervention":455,"totalTrials":231,"cells":456},"Warfarin",{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":463,"PHASE4":485,"NA":487},{"trials":458,"activeCount":81},[],{"trials":460,"activeCount":81},[],{"trials":462,"activeCount":81},[],{"trials":464,"activeCount":81},[465,475],{"nctId":466,"briefTitle":467,"status":246,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT00129545","WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation",[71,72],"2013-08","2014-05","2005-02",800,[21,182],[455],{"nctId":476,"briefTitle":477,"status":246,"phases":478,"primaryCompletion":479,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":484},"NCT01182441","Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy",[72],"2013-01","2017-11","2010-11",407,[21,182],[455],{"trials":486,"activeCount":81},[],{"trials":488,"activeCount":81},[],{"intervention":490,"totalTrials":231,"cells":491},"Sorafenib",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":519,"NA":521},{"trials":493,"activeCount":81},[],{"trials":495,"activeCount":81},[],{"trials":497,"activeCount":81},[],{"trials":499,"activeCount":81},[500,510],{"nctId":501,"briefTitle":502,"status":258,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":231,"conditions":506,"interventions":509},"NCT02460991","A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma",[72],"2017-06-05","2015-11",[136,507,508],"Hepatoma","Liver Cell Carcinoma",[490],{"nctId":511,"briefTitle":512,"status":258,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":518},"NCT01887717","Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein",[72],"2017-05-23","2014-02-27",36,[136],[490],{"trials":520,"activeCount":81},[],{"trials":522,"activeCount":81},[],{"intervention":524,"totalTrials":77,"cells":525},"Drug Eluting Stent - Below the Knee",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":545,"NA":547},{"trials":527,"activeCount":81},[],{"trials":529,"activeCount":81},[],{"trials":531,"activeCount":81},[],{"trials":533,"activeCount":81},[534],{"nctId":535,"briefTitle":536,"status":246,"phases":537,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":544},"NCT03551496","The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia",[72],"2022-04-21","2023-12-20","2018-08-31",201,[543],"Critical Limb Ischemia",[524],{"trials":546,"activeCount":81},[],{"trials":548,"activeCount":81},[],{"intervention":550,"totalTrials":77,"cells":551},"Anti-platelet therapy",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":572,"NA":574},{"trials":553,"activeCount":81},[],{"trials":555,"activeCount":81},[],{"trials":557,"activeCount":81},[],{"trials":559,"activeCount":81},[560],{"nctId":561,"briefTitle":562,"status":246,"phases":563,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},"NCT00896337","EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries",[72],"2011-09","2013-12","2009-05",125,[569],"Iliac Artery Stenosis",[550,571],"Anti-coagulation therapy",{"trials":573,"activeCount":81},[],{"trials":575,"activeCount":81},[],{"intervention":571,"totalTrials":77,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":590,"NA":592},{"trials":579,"activeCount":81},[],{"trials":581,"activeCount":81},[],{"trials":583,"activeCount":81},[],{"trials":585,"activeCount":81},[586],{"nctId":561,"briefTitle":562,"status":246,"phases":587,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":588,"interventions":589},[72],[569],[550,571],{"trials":591,"activeCount":81},[],{"trials":593,"activeCount":81},[],{"intervention":595,"totalTrials":77,"cells":596},"Unfractionated heparin",{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":616,"NA":618},{"trials":598,"activeCount":81},[],{"trials":600,"activeCount":81},[],{"trials":602,"activeCount":81},[],{"trials":604,"activeCount":81},[605],{"nctId":606,"briefTitle":607,"status":246,"phases":608,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":615},"NCT01166997","ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism",[72],"2013-04","2013-05","2010-07",59,[614],"Submassive Pulmonary Embolism",[595],{"trials":617,"activeCount":81},[],{"trials":619,"activeCount":81},[],{"intervention":621,"totalTrials":77,"cells":622},"endovenous ablation+polidocanol injectable microfoam 0.125%",{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":644,"NA":646},{"trials":624,"activeCount":81},[],{"trials":626,"activeCount":81},[],{"trials":628,"activeCount":81},[],{"trials":630,"activeCount":81},[631],{"nctId":632,"briefTitle":633,"status":246,"phases":634,"primaryCompletion":635,"completion":636,"start":426,"enrollment":637,"conditions":638,"interventions":641},"NCT01197833","Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities",[72],"2012-03","2012-12",117,[639,640],"Great Saphenous Vein Incompetence","Visible Varicosities",[621,642,643],"Endovenous ablation+polidocanol injectable microfoam 1.0%","Endovenous ablation+polidocanol injectable foam 2.0%",{"trials":645,"activeCount":81},[],{"trials":647,"activeCount":81},[],{"intervention":642,"totalTrials":77,"cells":649},{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":662,"NA":664},{"trials":651,"activeCount":81},[],{"trials":653,"activeCount":81},[],{"trials":655,"activeCount":81},[],{"trials":657,"activeCount":81},[658],{"nctId":632,"briefTitle":633,"status":246,"phases":659,"primaryCompletion":635,"completion":636,"start":426,"enrollment":637,"conditions":660,"interventions":661},[72],[639,640],[621,642,643],{"trials":663,"activeCount":81},[],{"trials":665,"activeCount":81},[],{"intervention":643,"totalTrials":77,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":680,"NA":682},{"trials":669,"activeCount":81},[],{"trials":671,"activeCount":81},[],{"trials":673,"activeCount":81},[],{"trials":675,"activeCount":81},[676],{"nctId":632,"briefTitle":633,"status":246,"phases":677,"primaryCompletion":635,"completion":636,"start":426,"enrollment":637,"conditions":678,"interventions":679},[72],[639,640],[621,642,643],{"trials":681,"activeCount":81},[],{"trials":683,"activeCount":81},[],{"intervention":685,"totalTrials":77,"cells":686},"Varisolve",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":706,"NA":708},{"trials":688,"activeCount":81},[],{"trials":690,"activeCount":81},[],{"trials":692,"activeCount":81},[],{"trials":694,"activeCount":81},[695],{"nctId":696,"briefTitle":697,"status":246,"phases":698,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":704},"NCT00758420","Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence",[71,72],"2009-07","2009-08","2008-10",77,[253],[685,705],"Agitated Saline",{"trials":707,"activeCount":81},[],{"trials":709,"activeCount":81},[],{"intervention":705,"totalTrials":77,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":724,"NA":726},{"trials":713,"activeCount":81},[],{"trials":715,"activeCount":81},[],{"trials":717,"activeCount":81},[],{"trials":719,"activeCount":81},[720],{"nctId":696,"briefTitle":697,"status":246,"phases":721,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":722,"interventions":723},[71,72],[253],[685,705],{"trials":725,"activeCount":81},[],{"trials":727,"activeCount":81},[],{"intervention":729,"totalTrials":77,"cells":730},"Paclitaxel",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":753,"NA":755},{"trials":732,"activeCount":81},[],{"trials":734,"activeCount":81},[],{"trials":736,"activeCount":81},[],{"trials":738,"activeCount":81},[739],{"nctId":740,"briefTitle":741,"status":246,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":752},"NCT03064126","RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty",[72],"2019-11-18","2023-10-25","2017-03-02",440,[748,29,749,750,751],"Peripheral Artery Disease","Artery Diseases, Peripheral","Plaque, Atherosclerotic","Occlusive Arterial Disease",[729],{"trials":754,"activeCount":81},[],{"trials":756,"activeCount":81},[],{"intervention":758,"totalTrials":77,"cells":759},"polidocanol injectable foam, 0.125%",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":778,"NA":780},{"trials":761,"activeCount":81},[],{"trials":763,"activeCount":81},[],{"trials":765,"activeCount":81},[],{"trials":767,"activeCount":81},[768],{"nctId":769,"briefTitle":770,"status":246,"phases":771,"primaryCompletion":564,"completion":377,"start":481,"enrollment":772,"conditions":773,"interventions":774},"NCT01231373","Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence",[72],235,[253],[758,775,776,777],"polidocanol injectable foam, 0.5%","polidocanol injectable foam, 1.0%","Vehicle",{"trials":779,"activeCount":81},[],{"trials":781,"activeCount":81},[],{"intervention":775,"totalTrials":77,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":796,"NA":798},{"trials":785,"activeCount":81},[],{"trials":787,"activeCount":81},[],{"trials":789,"activeCount":81},[],{"trials":791,"activeCount":81},[792],{"nctId":769,"briefTitle":770,"status":246,"phases":793,"primaryCompletion":564,"completion":377,"start":481,"enrollment":772,"conditions":794,"interventions":795},[72],[253],[758,775,776,777],{"trials":797,"activeCount":81},[],{"trials":799,"activeCount":81},[],{"intervention":776,"totalTrials":77,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":814,"NA":816},{"trials":803,"activeCount":81},[],{"trials":805,"activeCount":81},[],{"trials":807,"activeCount":81},[],{"trials":809,"activeCount":81},[810],{"nctId":769,"briefTitle":770,"status":246,"phases":811,"primaryCompletion":564,"completion":377,"start":481,"enrollment":772,"conditions":812,"interventions":813},[72],[253],[758,775,776,777],{"trials":815,"activeCount":81},[],{"trials":817,"activeCount":81},[],{"intervention":777,"totalTrials":77,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":832,"NA":834},{"trials":821,"activeCount":81},[],{"trials":823,"activeCount":81},[],{"trials":825,"activeCount":81},[],{"trials":827,"activeCount":81},[828],{"nctId":769,"briefTitle":770,"status":246,"phases":829,"primaryCompletion":564,"completion":377,"start":481,"enrollment":772,"conditions":830,"interventions":831},[72],[253],[758,775,776,777],{"trials":833,"activeCount":81},[],{"trials":835,"activeCount":81},[],{"intervention":837,"totalTrials":77,"cells":838},"Polidocanol injectable foam",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":856,"NA":858},{"trials":840,"activeCount":81},[],{"trials":842,"activeCount":81},[],{"trials":844,"activeCount":81},[],{"trials":846,"activeCount":81},[847],{"nctId":848,"briefTitle":849,"status":246,"phases":850,"primaryCompletion":851,"completion":852,"start":351,"enrollment":853,"conditions":854,"interventions":855},"NCT01072877","Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence",[72],"2011-12","2012-11",279,[253],[837],{"trials":857,"activeCount":81},[],{"trials":859,"activeCount":81},[],{"intervention":861,"totalTrials":231,"cells":862},"OncoGel",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":892,"PHASE4":894,"NA":896},{"trials":864,"activeCount":81},[],{"trials":866,"activeCount":81},[],{"trials":868,"activeCount":81},[869,882],{"nctId":870,"briefTitle":871,"status":258,"phases":872,"primaryCompletion":481,"completion":481,"start":873,"enrollment":874,"conditions":875,"interventions":879},"NCT00573131","Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer",[71],"2008-01",137,[876,877,878],"Esophageal Cancer","Adenocarcinoma of the Esophagus","Squamous Cell Carcinoma",[861,880,881],"cisplatin","5-FU",{"nctId":883,"briefTitle":884,"status":258,"phases":885,"primaryCompletion":446,"completion":446,"start":886,"enrollment":887,"conditions":888,"interventions":891},"NCT00479765","A Phase 1 \u002F 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma",[70,71],"2007-03",4,[889,890],"Glioblastoma Multiforme","Brain Neoplasms",[861],{"trials":893,"activeCount":81},[],{"trials":895,"activeCount":81},[],{"trials":897,"activeCount":81},[],{"intervention":880,"totalTrials":77,"cells":899},{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":901,"activeCount":81},[],{"trials":903,"activeCount":81},[],{"trials":905,"activeCount":81},[906],{"nctId":870,"briefTitle":871,"status":258,"phases":907,"primaryCompletion":481,"completion":481,"start":873,"enrollment":874,"conditions":908,"interventions":909},[71],[876,877,878],[861,880,881],{"trials":911,"activeCount":81},[],{"trials":913,"activeCount":81},[],{"trials":915,"activeCount":81},[],{"intervention":881,"totalTrials":77,"cells":917},{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":919,"activeCount":81},[],{"trials":921,"activeCount":81},[],{"trials":923,"activeCount":81},[924],{"nctId":870,"briefTitle":871,"status":258,"phases":925,"primaryCompletion":481,"completion":481,"start":873,"enrollment":874,"conditions":926,"interventions":927},[71],[876,877,878],[861,880,881],{"trials":929,"activeCount":81},[],{"trials":931,"activeCount":81},[],{"trials":933,"activeCount":81},[],{"intervention":935,"totalTrials":77,"cells":936},"BGC20-0582",{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":954,"PHASE4":956,"NA":958},{"trials":938,"activeCount":81},[],{"trials":940,"activeCount":81},[],{"trials":942,"activeCount":81},[943],{"nctId":944,"briefTitle":945,"status":246,"phases":946,"primaryCompletion":947,"completion":948,"start":352,"enrollment":949,"conditions":950,"interventions":953},"NCT00528021","A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation",[71],"2008-05","2008-06",230,[951,952],"Pediculus Humanus Capitis","Head Lice",[935],{"trials":955,"activeCount":81},[],{"trials":957,"activeCount":81},[],{"trials":959,"activeCount":81},[],{"intervention":961,"totalTrials":77,"cells":962},"Polidocanol",{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":964,"activeCount":81},[],{"trials":966,"activeCount":81},[],{"trials":968,"activeCount":81},[969],{"nctId":970,"briefTitle":971,"status":246,"phases":972,"primaryCompletion":948,"completion":700,"start":886,"enrollment":973,"conditions":974,"interventions":975},"NCT00442364","Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt",[71],60,[253],[961],{"trials":977,"activeCount":81},[],{"trials":979,"activeCount":81},[],{"trials":981,"activeCount":81},[],{"intervention":983,"totalTrials":77,"cells":984},"BGC20-1531",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":986,"activeCount":81},[],{"trials":988,"activeCount":81},[],{"trials":990,"activeCount":81},[991],{"nctId":992,"briefTitle":993,"status":349,"phases":994,"enrollment":81,"conditions":995,"interventions":997},"NCT00888680","Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine",[71],[996],"Migraine",[983,998],"Lactose",{"trials":1000,"activeCount":81},[],{"trials":1002,"activeCount":81},[],{"trials":1004,"activeCount":81},[],{"intervention":998,"totalTrials":77,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1017,"PHASE4":1019,"NA":1021},{"trials":1008,"activeCount":81},[],{"trials":1010,"activeCount":81},[],{"trials":1012,"activeCount":81},[1013],{"nctId":992,"briefTitle":993,"status":349,"phases":1014,"enrollment":81,"conditions":1015,"interventions":1016},[71],[996],[983,998],{"trials":1018,"activeCount":81},[],{"trials":1020,"activeCount":81},[],{"trials":1022,"activeCount":81},[],{"intervention":1024,"totalTrials":77,"cells":1025},"Pleneva TM BGC20-0134",{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1027,"activeCount":81},[],{"trials":1029,"activeCount":81},[],{"trials":1031,"activeCount":81},[1032],{"nctId":1033,"briefTitle":1034,"status":258,"phases":1035,"primaryCompletion":851,"completion":851,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1040},"NCT01037907","A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",[71],"2009-11",173,[1039],"Relapsing Remitting Multiple Sclerosis",[1024],{"trials":1042,"activeCount":81},[],{"trials":1044,"activeCount":81},[],{"trials":1046,"activeCount":81},[],{"intervention":1048,"totalTrials":77,"cells":1049},"Polidocanol Endovenous Microfoam 0.125%",{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1051,"activeCount":81},[],{"trials":1053,"activeCount":81},[],{"trials":1055,"activeCount":81},[1056],{"nctId":1057,"briefTitle":1058,"status":246,"phases":1059,"primaryCompletion":1060,"completion":1061,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1065},"NCT00928421","An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins",[71],"2009-12","2010-01","2009-06",16,[253],[1048],{"trials":1067,"activeCount":81},[],{"trials":1069,"activeCount":81},[],{"trials":1071,"activeCount":81},[],{"intervention":1073,"totalTrials":77,"cells":1074},"Polidocanol Endovenous Microfoam",{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1088,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1076,"activeCount":81},[],{"trials":1078,"activeCount":81},[1079],{"nctId":1080,"briefTitle":1081,"status":246,"phases":1082,"primaryCompletion":1083,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1087},"NCT01428076","Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)",[70],"2012-01","2011-08",21,[253],[1073],{"trials":1089,"activeCount":81},[],{"trials":1091,"activeCount":81},[],{"trials":1093,"activeCount":81},[],{"trials":1095,"activeCount":81},[],{"intervention":1097,"totalTrials":77,"cells":1098},"BTG-002814",{"EARLY_PHASE1":1099,"PHASE1":1112,"PHASE2":1114,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1100,"activeCount":81},[1101],{"nctId":1102,"briefTitle":1103,"status":246,"phases":1104,"primaryCompletion":1105,"completion":1105,"start":1106,"enrollment":1107,"conditions":1108,"interventions":1111},"NCT03291379","Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies",[69],"2019-08-03","2017-05-17",8,[1109,1110],"Carcinoma, Hepatocellular","Metastatic Colorectal Cancer",[1097],{"trials":1113,"activeCount":81},[],{"trials":1115,"activeCount":81},[],{"trials":1117,"activeCount":81},[],{"trials":1119,"activeCount":81},[],{"trials":1121,"activeCount":81},[],{"intervention":383,"totalTrials":1123,"cells":1124},5,{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1131,"PHASE4":1145,"NA":1151},{"trials":1126,"activeCount":81},[],{"trials":1128,"activeCount":81},[],{"trials":1130,"activeCount":81},[],{"trials":1132,"activeCount":81},[1133,1137,1141],{"nctId":423,"briefTitle":424,"status":246,"phases":1134,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":1135,"interventions":1136},[72],[15],[383,411],{"nctId":433,"briefTitle":434,"status":246,"phases":1138,"primaryCompletion":436,"completion":250,"start":437,"enrollment":438,"conditions":1139,"interventions":1140},[72],[15],[383,411],{"nctId":442,"briefTitle":443,"status":246,"phases":1142,"primaryCompletion":445,"completion":250,"start":446,"enrollment":447,"conditions":1143,"interventions":1144},[72],[15],[383,411],{"trials":1146,"activeCount":81},[1147],{"nctId":374,"briefTitle":375,"status":246,"phases":1148,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":1149,"interventions":1150},[73],[15],[383,361],{"trials":1152,"activeCount":81},[1153],{"nctId":1154,"briefTitle":1155,"status":246,"phases":1156,"primaryCompletion":1157,"completion":1158,"start":1060,"enrollment":1159,"conditions":1160,"interventions":1161},"NCT00997503","TAXUS Libertē Post Approval Study",[],"2013-03","2015-07",4199,[15],[1162,1163],"prasugrel","aspirin",{"intervention":1165,"totalTrials":77,"cells":1166},"Acetylsalicylic Acid",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1173,"PHASE4":1175,"NA":1177},{"trials":1168,"activeCount":81},[],{"trials":1170,"activeCount":81},[],{"trials":1172,"activeCount":81},[],{"trials":1174,"activeCount":81},[],{"trials":1176,"activeCount":81},[],{"trials":1178,"activeCount":81},[1179],{"nctId":1180,"briefTitle":1181,"status":349,"phases":1182,"primaryCompletion":1183,"completion":1184,"start":1185,"enrollment":81,"conditions":1186,"interventions":1188},"NCT04059536","Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)",[],"2019-12-01","2020-03-31","2019-10-31",[1187,29,15,748],"Chronic Total Occlusion",[1165,1189],"Heparin",{"intervention":1189,"totalTrials":77,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1193,"activeCount":81},[],{"trials":1195,"activeCount":81},[],{"trials":1197,"activeCount":81},[],{"trials":1199,"activeCount":81},[],{"trials":1201,"activeCount":81},[],{"trials":1203,"activeCount":81},[1204],{"nctId":1180,"briefTitle":1181,"status":349,"phases":1205,"primaryCompletion":1183,"completion":1184,"start":1185,"enrollment":81,"conditions":1206,"interventions":1207},[],[1187,29,15,748],[1165,1189],{"intervention":1209,"totalTrials":77,"cells":1210},"Medical management",{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1212,"activeCount":81},[],{"trials":1214,"activeCount":81},[],{"trials":1216,"activeCount":81},[],{"trials":1218,"activeCount":81},[],{"trials":1220,"activeCount":81},[],{"trials":1222,"activeCount":81},[1223],{"nctId":1224,"briefTitle":1225,"status":246,"phases":1226,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":1229,"conditions":1230,"interventions":1231},"NCT00231296","Safety and Efficacy of CryoCor™ Cryoablation for PAF",[74],"2009-03","2004-11",174,[21],[1209],{"intervention":1233,"totalTrials":77,"cells":1234},"Varithena",{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1239,"PHASE3":1241,"PHASE4":1243,"NA":1245},{"trials":1236,"activeCount":81},[],{"trials":1238,"activeCount":81},[],{"trials":1240,"activeCount":81},[],{"trials":1242,"activeCount":81},[],{"trials":1244,"activeCount":81},[],{"trials":1246,"activeCount":81},[1247],{"nctId":1248,"briefTitle":1249,"status":246,"phases":1250,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":1255,"interventions":1257},"NCT03257254","Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)",[],"2020-05-18","2020-09-28","2017-09-29",76,[1256],"Venous Leg Ulcer",[1233],{"intervention":1259,"totalTrials":77,"cells":1260},"Control",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1262,"activeCount":81},[],{"trials":1264,"activeCount":81},[],{"trials":1266,"activeCount":81},[],{"trials":1268,"activeCount":81},[],{"trials":1270,"activeCount":81},[],{"trials":1272,"activeCount":81},[1273],{"nctId":1274,"briefTitle":1275,"status":246,"phases":1276,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1283},"NCT00214539","Research in Severe Asthma (RISA) Trial",[74],"2006-02","2006-08","2004-04",34,[1282],"Asthma",[1259],{"intervention":1285,"totalTrials":77,"cells":1286},"Market-approved OAC",{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1288,"activeCount":81},[],{"trials":1290,"activeCount":81},[],{"trials":1292,"activeCount":81},[],{"trials":1294,"activeCount":81},[],{"trials":1296,"activeCount":81},[],{"trials":1298,"activeCount":81},[1299],{"nctId":1300,"briefTitle":1301,"status":246,"phases":1302,"primaryCompletion":1303,"completion":1303,"start":1304,"enrollment":1305,"conditions":1306,"interventions":1307},"NCT03795298","Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation",[74],"2024-07-24","2019-05-20",1600,[21],[1285],{"intervention":1162,"totalTrials":77,"cells":1309},{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1318,"NA":1320},{"trials":1311,"activeCount":81},[],{"trials":1313,"activeCount":81},[],{"trials":1315,"activeCount":81},[],{"trials":1317,"activeCount":81},[],{"trials":1319,"activeCount":81},[],{"trials":1321,"activeCount":81},[1322],{"nctId":1154,"briefTitle":1155,"status":246,"phases":1323,"primaryCompletion":1157,"completion":1158,"start":1060,"enrollment":1159,"conditions":1324,"interventions":1325},[],[15],[1162,1163],{"intervention":1327,"totalTrials":77,"cells":1328},"Single Antiplatelet Therapy or No Therapy",{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1339},{"trials":1330,"activeCount":81},[],{"trials":1332,"activeCount":81},[],{"trials":1334,"activeCount":81},[],{"trials":1336,"activeCount":81},[],{"trials":1338,"activeCount":81},[],{"trials":1340,"activeCount":81},[1341],{"nctId":1342,"briefTitle":1343,"status":246,"phases":1344,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":1347,"conditions":1348,"interventions":1349},"NCT02928497","Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation",[74],"2025-09-23","2017-02-06",481,[182],[1327]]